The phase 3 LIGHTHOUSE study is a randomized, open-label, phase 3 study of melflufen and dexamethasone in combination with daratumumab compared to daratumumab alone in patients with relapsed and refractory multiple myeloma (RRMM) who are refractory to an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI) or who have had at least three prior lines of therapy, including an IMiD and a PI.

The aim is to investigate the efficacy and safety of a combination therapy with melflufen plus daratumumab compared to daratumumab.

The study recruited its first patient in December 2020.

LIGHTHOUSE will close with incomplete number of patients, it will not be possible to draw any relevant scientific conclusions from these data sets.